High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? A Systematic Literature Review

Introduction Influenza is a respiratory infection associated with a significant clinical burden globally. Adults aged ≥ 65 years are at increased risk of severe influenza-related symptoms and complications due to chronic comorbidity and immunosenescence. Annual influenza vaccination is recommended; however, current influenza vaccines confer suboptimal protection, in part due to antigen mismatch and poor durability. This systematic literature review characterizes the global clinical burden of seasonal influenza among adults aged ≥ 65 years. Methods An electronic database search was conducted and supplemented with a conference abstract search. Included studies described clinical outcomes in the ≥ 65 years population across several global regions and were published in English between January 1, 2012 and February 9, 2022. Results Ninety-nine publications were included (accounting for > 156,198,287 total participants globally). Clinical burden was evident across regions, with most studies conducted in the USA and Europe. Risk of influenza-associated hospitalization increased with age, particularly in those aged ≥ 65 years living in long-term care facilities, with underlying comorbidities, and infected with A(H3N2) strains. Seasons dominated by circulating A(H3N2) strains saw increased risk of influenza-associated hospitalization, intensive care unit admission, and mortality within the ≥ 65 years population. Seasonal differences in clinical burden were linked to differences in circulating strains. Conclusions Influenza exerts a considerable burden on adults aged ≥ 65 years and healthcare systems, with high incidence of hospitalization and mortality. Substantial influenza-associated clinical burden persists despite increasing vaccination coverage among adults aged ≥ 65 years across regions included in this review, which suggests limited effectiveness of currently available seasonal influenza vaccines. To reduce influenza-associated clinical burden, influenza vaccine effectiveness must be improved. Next generation vaccine production using mRNA technology has demonstrated high effectiveness against another respiratory virus—SARS-CoV-2—and may overcome the practical limitations associated with traditional influenza vaccine production..

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:40
Enthalten in:	Advances in therapy - 40(2023), 4 vom: 15. Feb., Seite 1601-1627

Sprache:	Englisch

Beteiligte Personen:	Langer, Jakob [VerfasserIn] Welch, Verna L. [VerfasserIn] Moran, Mary M. [VerfasserIn] Cane, Alejandro [VerfasserIn] Lopez, Santiago M. C. [VerfasserIn] Srivastava, Amit [VerfasserIn] Enstone, Ashley L. [VerfasserIn] Sears, Amy [VerfasserIn] Markus, Kristen J. [VerfasserIn] Heuser, Maria [VerfasserIn] Kewley, Rachel M. [VerfasserIn] Whittle, Isabelle J. [VerfasserIn]

Links:	Volltext [kostenfrei]

Themen:	Burden of disease Hospitalization MRNA vaccine Mortality Older adults Strain Vaccination

Anmerkungen:	© Pfizer Inc 2023

doi:	10.1007/s12325-023-02432-1

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	SPR049935518